From Breakingviews - Pfizer’s $43 bln deal is a pricey pipeline fix
, inclusive of net debt. Snag is, Pfizer’s return will probably be low, and the deal may not even receive antitrust approval.
Seagen’s pre-tax profit should be around $500 million in 2025, according to analyst estimates from Refinitiv. Add estimated savings of $1 billion and the result is $1.2 billion of operating profit after tax, assuming the statutory corporate rate. That’s about a 3% return on the purchase price, similar to what Breakingviews estimated when news of talks leaked in February.
Pfizer Chief Executive Albert Bourla is betting that plugging acquired drugs into its worldwide sales machine, and growth past 2025 from new drugs, will eventually generate an acceptable return on capital. That is probably optimistic considering analysts already guessed Seagen would double sales by 2025.
There’s an earlier barrier to jump. Seagen’s stock traded 13% below the $229 per share price on Monday morning, implying investors don’t view antitrust approval as certain. With Pfizer on the hook for a $2.2 billion fee if the deal doesn’t go ahead, Bourla is risking a lot for potentially little reward.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer Agrees to Buy Seagen for $43 BillionThe New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.
Read more »
Pfizer looks beyond COVID sales with $43 bln deal for cancer drugmaker SeagenPfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Read more »
Pfizer to buy cancer drugmaker Seagen for $43 billionNEW: Pfizer said it has agreed to buy cancer drugmaker Seagen for $43 billion in cash. It's the largest pharma deal since Abbvie bought Allergan in 2020.
Read more »
Pfizer buys Seagen for $43B, boosts access to cancer drugsPfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay $229 per Seagen share.
Read more »
Pfizer looks past COVID with $43 bln deal for cancer drug innovator SeagenPfizer Inc struck a $43 billion deal for Seagen Inc to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers.
Read more »
Pfizer buys Seagen for $43B, boosts access to cancer drugsPfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
Read more »